Autres langues Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8077

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
3,36 ^USD	+5,66%		+5,00%	+21,30%

14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Cellectar Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03
Cellectar Biosciences : Corporate Presentation - March 2024	18/03
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30/01
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25/01
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23/01
Sector Update: Health Care Stocks Advance Late Afternoon	22/01
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	22/01
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	22/01
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	22/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8077

Autres langues

Filtres